eneous® LDL Reager

FOR THE QUANTITATIVE MEASUREMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C)

METHOD: ENZYMATIC (DIRECT HOMOGENEOUS); ENDPOINT

LDL-C measurements are a useful tool in identifying patients at increased risk of coronary artery disease.

The Sekisui N-geneous® LDL assay is a homogeneous method for directly measuring LDL-C levels in serum or plasma, without the need for any off-line pre-treatment or centrifugation steps. The assay directly measures LDL-C levels in serum and plasma samples.

Features:

- Correlates to the Reference Method (Ultracentrifugation) and immunoseparation method
- Meets 1998 NCEP total error goals for both normal and high triglyceride samples
- Liquid stable, ready to use reagents
- Non-fasting serum or plasma samples are acceptable

Benefits:

- Confidence in results and correct classification of patients
- Easy to use, no additional preparation required
- Convenient and ensures accuracy regardless of patient fasting status

Performance Characteristics

Precision

Within-Run: ≤0.73% • Total Precision: ≤2.27%

Accuracy^(a)

- Slope: 0.95
- Intercept: 3.02 mg/dL (0.08 mmol/L)
- Correlation Coefficient: 0.96

Linearity

• 6.6-992 mg/dL (0.17-25.65 mmol/L)

No Significant Interferences Up to Levels Indicated

- Triglyceride: 1293 mg/dL (14.6 mmol/L)
- Ascorbic Acid: 50 mg/dL (2840 µmol/L)
- Bilirubin: 20 mg/dL (342 µmol/L)
- Hemoglobin: 500 mg/dL (78 µmol/L)
- Gamma Globulins: 5000 mg/dL (50 g/L)

Reference Range(1)

LDL CHOLESTEROL

CLASSIFICATION

<130 ma/dL (3.36 mmol/L) Desirable 130-159 mg/dL (3.36-4.11 mmol/L) Borderline High Risk >160 mg/dL (4.14 mmol/L) High Risk

It is recommended that each laboratory establish the normal range for its patient population.

(a) The performance of this method (y) on a Roche/Hitachi® 911 analyzer was compared with the performance of the ultracentrifugation reference method (x)

CLINICAL CHEMISTRY REAGENTS

N-geneous® LDL Reagent

FOR THE QUANTITATIVE MEASUREMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C)

METHOD: ENZYMATIC (DIRECT HOMOGENEOUS); ENDPOINT

LDL-C measurements are a useful tool in identifying patients at increased risk of coronary artery disease.

The Sekisui N-geneous® LDL assay is a homogeneous method for directly measuring LDL-C levels in serum or plasma, without the need for any off-line pre-treatment or centrifugation steps. The assay directly measures LDL-C levels in serum and plasma samples.

Ordering information		
	Configuration	Catalog Number
N-geneous® LDL Cholesterol Reagent	R1 1 x 250 mL	80-4598-00
N-geneous® LDL Cholesterol Reagent	R2 1 x 80 mL	80-4601-00
LDL Direct Liquid Select Cholesterol Reagent	R1 1 x 30 mL R2 1 x 10 mL	7120
N-geneous® LDL Cholesterol Calibrator	3 x 1 mL	80-4601-02

⁽¹⁾ Bachorik P.S. et al. National Cholesterol Education Program Recommendations for Measurement of Low-Density Lipoprotein Cholesterol: Executive Summary. Clin Chem 1995; 41(10):1414.







Experience + Technology + Portfolio + Support =



THE AMERICAS

Sekisui Diagnostics, LLC One Wall Street Burlington, MA 01803 Phone: 800 332 1042 Fax: 800 762 6311

Email: questions@sekisui-dx.com

INTERNATIONAL

Sekisui Diagnostics (UK) Limited Liphook Way, Allington Maidstone, Kent, ME16 OLQ, UK Phone: +44 1622 607800 Fax: +44 1622 607801 Email: info@sekisui-dx.com DIAGNOSTICS

Because every result matters¹⁶

www.sekisuidiagnostics.com